BACKGROUND: There is currently no standard second-line treatment for @entity788 ( @entity788 ), and progression-free survival is consistently <4 months in this setting. The aim of this study was to evaluate the efficacy and tolerability of Nab- @entity1311 plus @entity136 (A+G) after Folfirinox failure in @entity788 . METHODS: From February 2013 to July 2014, all consecutive @entity1 treated with A+G for histologically proven @entity788 after Folfirinox failure were prospectively enrolled in 12 French centres. A+G was delivered as described in the MPACT trial, until disease progression, @entity1 refusal or unacceptable @entity137 . RESULTS: Fifty-seven @entity1 were treated with @entity34994 plus @entity136 , for a median of 4 cycles (range 1-12). The disease control rate was 58%, with a 17.5% objective response rate. Median @entity1349 ( @entity1349 ) was 8.8 months (95% CI: 6.2-9.7) and median progression-free survival was 5.1 months (95% CI: 3.2-6.2). Since the start of first-line chemotherapy, median @entity1349 was 18 months (95% CI: 16-21). No toxic @entity204 occurred. Grade 3-4 @entity137 were reported in 40% of @entity1 , consisting of @entity1398 (12.5%), @entity2359 (12.5%), @entity1395 (9%) and @entity882 (6.5%). CONCLUSIONS: A+G seems to be effective, with a manageable @entity137 profile, after Folfirinox failure in @entity1 with @entity788 advance online publication, 15 September 2015; doi:10.1038/bjc.2015.328 www.bjcancer.com.

Nab- XXXX plus @entity136 for @entity788 after Folfirinox failure: an AGEO prospective multicentre cohort.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['metastatic pancreatic adenocarcinoma', 'MPA.British Journal of Cancer', 'MPA'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity34994 :: ('MESH:C520255', 'Chemical') :: ['Nab-paclitaxel'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity2359 :: ('MESH:D020258', 'Disease') :: ['neurotoxicity'] @entity1395 :: ('MESH:D001247', 'Disease') :: ['asthenia'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
